FDA Grants Accelerated Approval to Tudriqev Plus Nivolumab for Advanced Melanoma After PD-1 Progression

TheBrief:

The FDA granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed during or after a PD-1-blocking regimen. The approval adds an intratumoral treatment option for a difficult-to-treat population, but continued approval depends on confirmatory evidence showing clinical benefit.

The August 6, 2026, decision makes vusolimogene oderparepvec (Tudriqev), given with nivolumab, available in the United States for the population defined in the prescribing information. Its immediate relevance is narrow but important: patients must have disease that cannot be resected, prior PD-1 exposure with subsequent progression, and tumors suitable for intralesional treatment.

The FDA used the accelerated approval pathway because the registration evidence showed tumor responses and durable responses rather than a demonstrated improvement in overall survival or another direct measure of clinical benefit. Continued approval is contingent on confirmatory evidence. Clinicians and health systems therefore need to distinguish regulatory availability from definitive proof that the regimen extends life or improves quality of life.

A response-based approval after PD-1 progression

The supporting evidence came from an open-label, single-arm cohort of patients with advanced melanoma whose disease had progressed after anti–PD-1 therapy. All participants received vusolimogene oderparepvec plus nivolumab; there was no randomized control group.

Vusolimogene oderparepvec is an engineered oncolytic viral immunotherapy administered directly into accessible tumors. It is intended to infect and disrupt tumor cells while promoting an antitumor immune response. Nivolumab continues PD-1 blockade, with the rationale that viral treatment may increase immune recognition in tumors that previously failed to respond or stopped responding to checkpoint inhibition.

The reported objective response rate was 32.9% among 140 treated patients, with a 95% confidence interval of 25.2% to 41.3%. Complete responses occurred in 15.0%. Median duration of response was reported as 33.7 months, with a 95% confidence interval extending from 14.1 months to not reached. The primary analysis included at least eight months of follow-up for every participant.

Responses are clinically meaningful in a population with limited options after PD-1 failure, particularly when they are complete and durable. They are not, however, equivalent to evidence of longer survival. Without a concurrent comparator, the study cannot establish that the combination caused better survival, symptom control or quality of life than another treatment strategy.

How the evidence was generated

The registration cohort was part of an early-phase, multicohort study rather than a randomized confirmatory trial. Eligibility selected patients with advanced melanoma previously treated with PD-1 blockade and with lesions that could be injected, including deeper lesions when image-guided administration was feasible under the protocol.

Tumor response was assessed according to prespecified radiographic criteria, with objective response rate and duration of response serving as the central efficacy measures. These endpoints can support accelerated approval when the FDA judges them reasonably likely to predict clinical benefit in a serious disease with unmet need.

This design can show whether substantial and lasting tumor shrinkage occurs after treatment. It cannot reliably quantify benefit relative to other salvage approaches. Cross-trial comparisons are especially uncertain because post–PD-1 melanoma populations differ in prior CTLA-4 exposure, resistance pattern, disease burden, lactate dehydrogenase level, brain metastases, injectable disease and subsequent treatment.

Safety must also be interpreted without a control arm. Grade 3 or 4 treatment-related adverse events were reported in 12.9% of participants. Lower-grade systemic and administration-related effects were more common. Because this is a replication-competent oncolytic viral product delivered into tumors, the FDA prescribing information should guide lesion handling, infection-control precautions, monitoring and management of treatment-related toxicity.

Where the combination may fit

The approval creates a treatment option after anti–PD-1 progression rather than replacing established first-line immunotherapy. Its practical niche is likely to be patients with unresectable cutaneous melanoma who have one or more safely injectable lesions and for whom continued checkpoint-based immunotherapy combined with local viral treatment is clinically appropriate.

Treatment selection after PD-1 failure remains individualized. Relevant considerations include BRAF mutation status, prior CTLA-4 therapy, tempo and distribution of progression, central nervous system involvement, performance status, comorbidities and access to injectable tumors. Available alternatives may include checkpoint combinations, molecularly targeted therapy for tumors with actionable alterations, local treatment, surgery in selected circumstances and clinical trials.

The need for intratumoral administration affects implementation. Oncology programs require expertise in lesion selection, serial injection and handling of an oncolytic viral agent. Superficial cutaneous, subcutaneous or nodal deposits may be straightforward to access, whereas visceral lesions can require imaging support and additional procedural resources. Patients without injectable disease are not represented by the core treatment concept and may not be candidates under the label.

Coverage and pathway decisions should reflect the conditional nature of the evidence. A response-based accelerated approval supports access, but it does not resolve comparative effectiveness or cost-effectiveness. Health systems may reasonably track treatment delivery, response duration, hospital use, serious toxicity and subsequent therapy while confirmatory results mature.

Important limits and unanswered questions

The principal limitation is the absence of randomization. Selection bias, differences in prior therapy and the natural history of individual tumors can influence observed response and durability. The modest sample size limits precision for uncommon toxicities and for clinically important subgroups. Patients enrolled in an intratumoral-therapy study may also differ from the broader PD-1–refractory population because they must have accessible disease and adequate fitness for study procedures.

The study was not designed to establish an overall-survival advantage, and mature comparative data on progression, symptoms and quality of life are lacking. The contribution of each component is also uncertain: because every participant received both treatments, the cohort does not isolate the effect of vusolimogene oderparepvec from nivolumab rechallenge or continued PD-1 blockade.

Confirmatory evidence should determine whether the response signal translates into direct clinical benefit and clarify which patients benefit most. A randomized comparison would be most informative, with overall survival, progression-free survival, durable disease control, patient-reported outcomes and safety among key endpoints. Failure to verify benefit can lead the FDA to modify or withdraw an accelerated approval.

Questions clinicians ask

Is this a new first-line treatment for advanced melanoma?

No. The approval applies after progression on PD-1 therapy in the population specified by the FDA label. The supporting study did not compare the combination with standard first-line regimens, so it does not justify moving vusolimogene oderparepvec ahead of established initial systemic therapy.

Does a 32.9% response rate prove that patients live longer?

No. Objective response and response duration supported accelerated approval because they were considered reasonably likely to predict benefit. A single-arm response rate cannot demonstrate an overall-survival advantage, and the apparent durability must be verified in confirmatory research with an appropriate comparator.

Which patients are most likely to be considered for treatment?

The practical candidates are patients with unresectable melanoma that progressed after PD-1 therapy and with lesions suitable for repeated intratumoral administration. Disease distribution, previous treatments, molecular findings, central nervous system involvement, procedural feasibility and the exact FDA label remain central to selection.

What should clinicians tell patients about the approval status?

The combination is FDA approved, but through a conditional pathway based on tumor response rather than confirmed improvement in survival or quality of life. Discussions should acknowledge both the durable responses observed in some participants and the unresolved comparative benefits, risks and treatment burden.

References

1. Tudriqev — US Food and Drug Administration, 2026 2. A Study of RP1 Monotherapy and RP1 in Combination With Nivolumab in Patients With Solid Tumors — ClinicalTrials.gov, 2026 3. Accelerated Approval Program — US Food and Drug Administration, 2026